Burden of women's cancers in the group of twenty (G20) from 1990 to 2023: epidemiological trends and impact from fertility, quality of care, and survival

Meng-Long Li; Rui-Shu Tang; Nan Wang; Jin-Lei Qi; Hui-Ming He; Meng-Ying Guan; Miao Li; Bing-Qing Wu; Yeerlin Asihaer; Sten H. Vermund; Yi-Fei Hu

doi:10.1016/j.mmr.2026.100026

Your Location：

Home >

Browse articles >

Burden of women's cancers in the group of twenty (G20) from 1990 to 2023: epidemiological trends and impact from fertility, quality of care, and survival

RESEARCH | Updated：2026-05-11

- Burden of women's cancers in the group of twenty (G20) from 1990 to 2023: epidemiological trends and impact from fertility, quality of care, and survival
- Military Medical Research (2026)
- Affiliations：
  
  Department of Child, Adolescent Health and Maternal Care, School of Public Health, Capital Medical University, Beijing 100069, China
  Evidence-based Medicine Center, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China
  Department of Gynecology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
  National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 100050, China
  College of Public Health, University of South Florida, Tampa, FL 33612, USA
  Beijing Key Laboratory of Environment and Aging, Capital Medical University, Beijing 100069, China
- Author bio：
  
  *Yi-Fei Hu, huyifei@yahoo.com
- Funds：
- DOI：10.1016/j.mmr.2026.100026
  CLC：
- Received：30 September 2024，
  
  Accepted：26 March 2026，
  
  Published：2026-04
- Accepted：
Scan QR Code
Li ML, Tang RS, Wang N, Qi JL, He HM, Guan MY, et al. Burden of women’s cancers in the group of twenty (G20) from 1990 to 2023: epidemiological trends and impact from fertility, quality of care, and survival. Mil Med Res. 2026;13(1):100026.
DOI：

Li ML, Tang RS, Wang N, Qi JL, He HM, Guan MY, et al. Burden of women’s cancers in the group of twenty (G20) from 1990 to 2023: epidemiological trends and impact from fertility, quality of care, and survival. Mil Med Res. 2026;13(1):100026. DOI： 10.1016/j.mmr.2026.100026.

摘要

Abstract

Background:

Cancer in women represents a significant disease burden

posing challenges for prevention

treatment

and caregiving. This study aimed to analyze the epidemiological trends of the women’s cancer burden and the main influencing factors in the group of twenty (G20) from 1990 to 2023.

Methods:

Incidence

prevalence

mortality

and disability-adjusted life years (DALYs) for breast

cervical

uterine

and ovarian cancers

as well as fertility rates for G20 and its 98 locations

were sourced from the Global Burden of Disease Study 2023. Age-standardized rates (ASRs)

quality of care index (QCI)

and 5-year relative survival of integrated women’s cancers were calculated. Average annual percent changes (AAPCs) were used to determine the temporal trends by age and region. Decomposition analysis identified drivers of changes in case numbers

linear regression assessed the associations with DALY rate changes

and dominance analysis identified dominant predictors.

Results:

In 2023

the incidence

prevalence

mortality

and DALYs from women’s cancers in G20 were 3.29 [95% uncertainty interval (UI) 2.60–4.14]

26.71 (95% UI 21.99–32.40)

1.16 (95% UI 0.91–1.45)

and 36.58 million (95% UI 28.40–46.32)

respectively

with ASRs of 87.63/100

000 (95% UI 65.12–115.85)

706.16/100

000 (95% UI 555.75–890.02)

30.03/100

000 (95% UI 22.10–39.58)

and 994.79/100

000 (95% UI 728.43–1328.81). The QCI was 75.13 [95% confidence interval (CI) 73.67–76.59]

and the 5-year relative survival rate was 65.74% (95% CI 65.53–65.95). From 1990 to 2023

there was a significant increase in incidence

prevalence

mortality

and DALYs in G20

primarily driven by population growth. Age-standardized incidence rate

QCI

and 5-year relative survival increased

while age-standardized mortality and DALY rates decreased. Changes in prevalence rates of breast cancer and cervical cancer for women aged 15–49 years were positively associated with changes in DALY rates of women’s cancers

whereas changes in the total fertility rate were negatively associated. Dominance analysis confirmed these three factors consistently as dominant predictors between 1990 and 2023. Reducing the prevalence of breast and cervical cancers and increasing fertility among women aged 15–49 years could lower the overall DALY burden attributable to women’s cancer.

Conclusions:

The incidence

prevalence

mortality

and DALYs of women’s cancers in G20 have increased substantially from 1990 to 2023. Tailored prevention strategies should consider age and cancer type

emphasizing reproductive health for women of reproductive age.

关键词

Keywords

references

GBD 2023 Cancer Collaborators . The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023 . Lancet . 2025 ; 406 ( 10512 ): 1565 - 86 .

Bray F , Laversanne M , Sung H , Ferlay J , Siegel RL , Soerjomataram I , et al . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA Cancer J Clin . 2024 ; 74 ( 3 ): 229 - 63 .

Ginsburg O , Vanderpuye V , Beddoe AM , Bhoo-Pathy N , Bray F , Caduff C , et al . Women, power, and cancer: a Lancet commission . Lancet . 2023 ; 402 ( 10417 ): 2113 - 66 .

Kumar M , Mohapatra G , Giri AK . A comparative analysis of environmental sustainability in G20 nations using a comprehensive framework . Discov Sustain . 2025 ; 6 ( 1 ): 1027 .

Dieleman JL , Cowling K , Agyepong IA , Alkenbrack S , Bollyky TJ , Bump JB , et al . The G20 and development assistance for health: historical trends and crucial questions to inform a new era . Lancet . 2019 ; 394 ( 10193 ): 173 - 83 .

South Africa is right to put debt, climate and inequality at the heart of G20 . Nature . 2025 ; 647 ( 8090 ): 560 .

Guida F , Kidman R , Ferlay J , Schüz J , Soerjomataram I , Kithaka B , et al . Global and regional estimates of orphans attributed to maternal cancer mortality in 2020 . Nat Med . 2022 ; 28 ( 12 ): 2563 - 72 .

Azangou-Khyavy M , Ghasemi E , Rezaei N , Khanali J , Kolahi AA , Malekpour MR , et al . Global, regional, and national quality of care index of cervical and ovarian cancer: a systematic analysis for the global burden of disease study 1990-2019 . BMC Womens Health . 2024 ; 24 ( 1 ): 69 .

Fischerova D , Smet C , Scovazzi U , Sousa DN , Hundarova K , Haldorsen IS . Staging by imaging in gynecologic cancer and the role of ultrasound: an update of European joint consensus statements . Int J Gynecol Cancer . 2024 ; 34 ( 3 ): 363 - 78 .

Sun P , Yu C , Yin L , Chen Y , Sun Z , Zhang T , et al . Global, regional, and national burden of female cancers in women of childbearing age, 1990-2021: analysis of data from the global burden of disease study 2021 . EClinical Medicine . 2024 ; 74 : 102713 .

Tan N , Wu Y , Li B , Chen W . Burden of cancers in six female organs in China and worldwide . Chin Med J (Engl) . 2024 ; 137 ( 18 ): 2190 - 201 .

GBD 2021 Demographics Collaborators . Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 . Lancet . 2024 ; 403 ( 10440 ): 1989 - 2056 .

Azadnajafabad S , Saeedi Moghaddam S , Keykhaei M , Shobeiri P , Rezaei N , Ghasemi E , et al . Expansion of the quality of care index on breast cancer and its risk factors using the Global Burden of Disease Study 2019 . Cancer Med . 2023 ; 12 ( 2 ): 1729 - 43 .

Keykhaei M , Masinaei M , Mohammadi E , Azadnajafabad S , Rezaei N , Saeedi Moghaddam S , et al . A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990−2017 . Exp Hematol Oncol . 2021 ; 10 ( 1 ): 11 .

Zhu B , Gu H , Mao Z , Beeraka NM , Zhao X , Anand MP , et al . Global burden of gynaecological cancers in 2022 and projections to 2050 . J Glob Health . 2024 ; 14 : 04155 .

Brown SB , Hankinson SE . Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers . Steroids . 2015 ; 99 ( Pt A ): 8 - 10 .

Chlebowski RT , Anderson GL , Sarto GE , Haque R , Runowicz CD , Aragaki AK , et al . Continuous combined estrogen plus progestin and endometrial cancer: the women's health initiative randomized trial . J Natl Cancer Inst . 2016 ; 108 ( 3 ): djv350 .

GBD 2021 Fertility and Forecasting Collaborators . Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 . Lancet . 2024 ; 403 ( 10440 ): 2057 - 99 .

GBD 2023 Disease and Injury and Risk Factor Collaborators . Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 . Lancet . 2025 ; 406 ( 10513 ): 1873 - 922 .

GBD 2021 Causes of Death Collaborators . Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 . Lancet . 2024 ; 403 ( 10440 ): 2100 - 32 .

Lv B , Lan JX , Si YF , Ren YF , Li MY , Guo FF , et al . Epidemiological trends of subarachnoid hemorrhage at global, regional, and national level: a trend analysis study from 1990 to 2021 . Mil Med Res . 2024 ; 11 ( 1 ): 46 .

Murray CJL . The Global Burden of Disease Study at 30 years . Nat Med . 2022 ; 28 ( 10 ): 2019 - 26 .

Duan J , Ding R , Li M , Qi J , Yin P , Wang L , et al . Subnational evidence for the attributable burden of respiratory infections in China’s population under 20: challenges from particulate matter pollution . Environ Health (Wash) . 2024 ; 3 ( 2 ): 177 - 89 .

Asadzadeh Vostakolaei F , Karim-Kos HE , Janssen-Heijnen ML , Visser O , Verbeek AL , Kiemeney LA . The validity of the mortality-to-incidence ratio as a proxy for site-specific cancer survival . Eur J Public Health . 2011 ; 21 ( 5 ): 573 - 7 .

Chen W , Zheng R , Baade PD , Zhang S , Zeng H , Bray F , et al . Cancer statistics in China, 2015 . CA Cancer J Clin . 2016 ; 66 ( 2 ): 115 - 32 .

National Cancer Institute . Joinpoint trend analysis software method and parameters tab . 2025 . https://surveillance.cancer.gov/help/joinpoint/setting-parameters/method-and-parameters-tab https://surveillance.cancer.gov/help/joinpoint/setting-parameters/method-and-parameters-tab . Accessed 25 June, 2025 .

Li ML , Qi JL , Ma YQ , Shu W , Xiao HD , Wang LJ , et al . National age-specific mortality trends for cervical and breast cancers in urban-rural areas of China from 2009 to 2021: a population-based analysis . Mil Med Res . 2024 ; 11 ( 1 ): 55 .

Qi J , Li M , Wang L , Hu Y , Liu W , Long Z , et al . National and subnational trends in cancer burden in China, 2005−20: an analysis of national mortality surveillance data . Lancet Public Health . 2023 ; 8 ( 12 ): e943 - e55 .

Li M , He H , Zhao X , Guan M , Khattab NM , Elshishiney G , et al . Burden of liver cancer and underlying etiologies in China from 1990 to 2021: a systematic analysis from the Global Burden of Disease Study 2021 . Chin Med J (Engl) . 2026 ; 139 ( 3 ): 415 - 23 .

Das Gupta P . Standardization and decomposition of rates from cross-classified data . Genus . 1994 ; 50 ( 3-4 ): 171 - 96 .

Azen R , Budescu DV . The dominance analysis approach for comparing predictors in multiple regression . Psychol Methods . 2003 ; 8 ( 2 ): 129 - 48 .

Issa J , Van Ourti T , van Baal P , O’Donnell O . Ranking age-at-death distributions using dominance: robust evaluation of United States mortality trends, 2006−2021 . Demography . 2024 ; 61 ( 4 ): 1143 - 59 .

Li L , Shan T , Zhang D , Ma F . Nowcasting and forecasting global aging and cancer burden: analysis of data from the GLOBOCAN and Global Burden of Disease Study . J Natl Cancer Cent . 2024 ; 4 ( 3 ): 223 - 32 .

Ginsburg O , Bray F , Coleman MP , Vanderpuye V , Eniu A , Kotha SR , et al . The global burden of women's cancers: a grand challenge in global health . Lancet . 2017 ; 389 ( 10071 ): 847 - 60 .

Zhang W , Gao K , Fowkes FJI , Adeloye D , Rudan I , Song P , et al . Associated factors and global adherence of cervical cancer screening in 2019: a systematic analysis and modelling study . Global Health . 2022 ; 18 ( 1 ): 101 .

Mwanahamuntu MH , Sahasrabuddhe VV , Kapambwe S , Pfaendler KS , Chibwesha C , Mkumba G , et al . Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the Cervical Cancer Prevention Program in Zambia . PLoS Med . 2011 ; 8 ( 5 ): e1001032 .

Vermund SH , Kelley KF . Impact of HIV on human papillomavirus-mediated cervical disease progression . Aids . 2018 ; 32 ( 12 ): 1715 - 7 .

de Souza JA , Hunt B , Asirwa FC , Adebamowo C , Lopes G . Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries . J Clin Oncol . 2016 ; 34 ( 1 ): 6 - 13 .

Kruk ME , Gage AD , Arsenault C , Jordan K , Leslie HH , Roder-DeWan S , et al . High-quality health systems in the Sustainable Development Goals era: time for a revolution . The Lancet Global Health . 2018 ; 6 ( 11 ): e1196 - e252 .

GBD 2021 Tobacco Forecasting Collaborators . Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021 . Lancet Public Health . 2024 ; 9 ( 10 ): e729 - e44 .

Huang Z , Wang J , Liu H , Wang B , Qi M , Lyu Z , et al . Global trends in adolescent and young adult female cancer burden, 1990−2021: insights from the Global Burden of Disease study . ESMO Open . 2024 ; 9 ( 11 ): 103958 .

Zhao Y , Qiu P , Yan L , Li S , Yang Z , Zhang H , et al . Epidemiological trends of female breast and gynecologic cancers in adolescents and young adults in China from 1990 to 2019: results from the Global Burden of Disease Study 2019 . Front Oncol . 2022 ; 12 : 1003710 .

Kieu V , Stern C , Harris J , Jayasinghe Y , Bradford N , Cui W , et al . Australian fertility preservation guidelines for people with cancer 2022: review and recommendations . Med J Aust . 2022 ; 217 ( 11 ): 564 - 9 .

Morice P , Scambia G , Abu-Rustum NR , Acien M , Arena A , Brucker S , et al . Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE . Lancet Oncol . 2024 ; 25 ( 11 ): e602 - e10 .

Vannuccini S , Clifton VL , Fraser IS , Taylor HS , Critchley H , Giudice LC , et al . Infertility and reproductive disorders: impact of hormonal and inflammatory mechanisms on pregnancy outcome . Hum Reprod Update . 2016 ; 22 ( 1 ): 104 - 15 .

Practice Committee of the American Society for Reproductive Medicine . Fertility drugs and cancer: a guideline . Fertil Steril . 2024 ; 122 ( 3 ): 406 - 20 .

Shah R , Hanna NM , Loo CE , David M , Mafra A , Fink H , et al . The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis . Nat Cancer . 2025 ; 6 ( 1 ): 194 - 204 .

Ward ZJ , Walbaum M , Walbaum B , Guzmán MJ , Jiménez de la Jara J , Nervi B , et al . Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis . Lancet Oncol . 2021 ; 22 ( 10 ): 1427 - 37 .

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

The evolving burden of heart failure in China: a 34-year subnational analysis of trends and causes from the Global Burden of Disease Study 2023

Effect of early administration of tetracosactide on mortality and host response in critically ill patients requiring rescue surgery: a sensitivity analysis of the STOPSHOCK phase 3 randomized controlled trial

Nomogram for prediction of fatal outcome in patients with severe COVID-19: a multicenter study

Related Author

Mai-Geng Zhou

Yi-Chong Li

Yan Xu

Gui-Yuan Han

Yu Shi

Zhen-Ping Zhao

Xuan Yang

Graziella D’Arrigo

Related Institution

Clinical Research Center, Shenzhen Medical Academy of Research and Translation

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention

National Clinical Research Center for Cardiovascular Diseases, Heart Failure Ward, Fuwai Hospital Chinese Academy of Medical Sciences

Department of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong University

Institute of Clinical Physiology (IFC-CNR), Section of Rome

⁰